AMAG’s outlook brighter, analyst says

Shares of AMAG Pharmaceuticals Inc. rose after an analyst upgraded the stock. Robert W. Baird & Co.’s Christopher Raymond raised his rating to “outperform.’’ He said prescription data indicate that demand for AMAG’s Feraheme, an iron compound to treat anemia, is improving. Market share in pre-dialysis patients has increased, and more physicians expect to start using Feraheme in the next six months. He added that the Lexington company has an effective sales force. Last year, AMAG agreed to toughen the label for Feraheme, with warnings related to potential life-threatening hypersensitivity reactions and hypotension.